2016
Yield of repeat forward-view examination of the right side of the colon in screening and surveillance colonoscopy
Clark BT, Parikh ND, Laine L. Yield of repeat forward-view examination of the right side of the colon in screening and surveillance colonoscopy. Gastrointestinal Endoscopy 2016, 84: 126-132. PMID: 26769408, PMCID: PMC4912931, DOI: 10.1016/j.gie.2015.12.030.Peer-Reviewed Original ResearchConceptsAdenoma detection rateForward-view examinationOverall adenoma detection rateSecond examinationRight sideSurveillance colonoscopyAdditional adenomasWest Haven Veterans Affairs Medical CenterVeterans Affairs Medical CenterBoston Bowel Preparation Scale scoreDistal colon cancerNumber of patientsYears of ageDevelopment of cancerSecondary outcomesPrimary outcomeMen 50Prospective studySurveillance intervalsAdenoma detectionDetection rateMedical CenterInitial examinationPatientsColon cancer
2013
Natural history of acute upper GI bleeding due to tumours: short‐term success and long‐term recurrence with or without endoscopic therapy
Sheibani S, Kim JJ, Chen B, Park S, Saberi B, Keyashian K, Buxbaum J, Laine L. Natural history of acute upper GI bleeding due to tumours: short‐term success and long‐term recurrence with or without endoscopic therapy. Alimentary Pharmacology & Therapeutics 2013, 38: 144-150. PMID: 23710797, DOI: 10.1111/apt.12347.Peer-Reviewed Original ResearchConceptsUpper gastrointestinal bleedingEndoscopic therapyHaemodynamic instabilityMalignant tumorsBiopsy-proven malignant tumorsAcute upper GISubstantial blood lossLong-term recurrenceYears of ageInitial haemostasisRepeat hospitalisationActive bleedingGastrointestinal bleedingIndex hospitalisationEndoscopic findingsMetastatic diseaseUpper endoscopyBlood lossConsecutive patientsEndoscopic treatmentUpper GIEndoscopy databaseRisk factorsPatientsMultivariate analysis
2009
Prescription rates of protective co‐therapy for NSAID users at high GI risk and results of attempts to improve adherence to guidelines
LAINE L, CONNORS L, GRIFFIN MR, CURTIS SP, KAUR A, CANNON CP. Prescription rates of protective co‐therapy for NSAID users at high GI risk and results of attempts to improve adherence to guidelines. Alimentary Pharmacology & Therapeutics 2009, 30: 767-774. PMID: 19594486, DOI: 10.1111/j.1365-2036.2009.04090.x.Peer-Reviewed Original Research
2004
Ulcer formation with low-dose enteric-coated aspirin and the effect of COX-2 selective inhibition: A double-blind trial
Laine L, Maller ES, Yu C, Quan H, Simon T. Ulcer formation with low-dose enteric-coated aspirin and the effect of COX-2 selective inhibition: A double-blind trial. Gastroenterology 2004, 127: 395-402. PMID: 15300570, DOI: 10.1053/j.gastro.2004.05.001.Peer-Reviewed Original ResearchMeSH KeywordsAgedAnti-Inflammatory Agents, Non-SteroidalAspirinCyclooxygenase 2Cyclooxygenase 2 InhibitorsCyclooxygenase InhibitorsDouble-Blind MethodDrug Therapy, CombinationFemaleGastric MucosaHumansIbuprofenIncidenceIsoenzymesLactonesMaleMembrane ProteinsMiddle AgedOsteoarthritisProstaglandin-Endoperoxide SynthasesRisk FactorsStomach UlcerSulfonesTablets, Enteric-CoatedConceptsNonselective nonsteroidal anti-inflammatory drugsLow-dose aspirinCOX-2 selective inhibitorsDouble-blind trialUlcer incidenceNonselective NSAIDsLow-dose enteric-coated aspirinLow-dose aspirin usersCyclooxygenase-2 selective inhibitorSelective inhibitorNonsteroidal anti-inflammatory drugsEnteric-coated aspirinGastrointestinal mucosal injuryNumber of erosionsRisk of ulcerAnti-inflammatory drugsCOX-2 selective inhibitionYears of ageBaseline endoscopyAspirin usersDose aspirinErosive esophagitisCumulative incidenceMucosal injuryRepeat endoscopy
2000
Comparison of Upper Gastrointestinal Toxicity of Rofecoxib and Naproxen in Patients with Rheumatoid Arthritis
Bombardier C, Laine L, Reicin A, Shapiro D, Burgos-Vargas R, Davis B, Day R, Ferraz M, Hawkey C, Hochberg M, Kvien T, Schnitzer T. Comparison of Upper Gastrointestinal Toxicity of Rofecoxib and Naproxen in Patients with Rheumatoid Arthritis. New England Journal Of Medicine 2000, 343: 1520-1528. PMID: 11087881, DOI: 10.1056/nejm200011233432103.Peer-Reviewed Original ResearchMeSH KeywordsAdultArthritis, RheumatoidCardiovascular DiseasesCyclooxygenase 2Cyclooxygenase 2 InhibitorsCyclooxygenase InhibitorsDuodenal ObstructionFemaleGastric Outlet ObstructionGastrointestinal DiseasesGastrointestinal HemorrhageHumansIsoenzymesLactonesMaleMembrane ProteinsMiddle AgedNaproxenPeptic UlcerProportional Hazards ModelsProstaglandin-Endoperoxide SynthasesSulfonesConceptsUpper gastrointestinal eventsNonselective nonsteroidal antiinflammatory drugsGastrointestinal eventsRheumatoid arthritisCyclooxygenase-2Upper gastrointestinal toxicityPercent of patientsPrimary end pointOverall mortality rateNonsteroidal antiinflammatory drugsRate of deathYears of ageNonselective NSAID naproxenSelective inhibitorCardiovascular causesRofecoxib groupGastrointestinal toxicityNaproxen groupMyocardial infarctionSimilar efficacyAntiinflammatory drugsLower incidenceArthritisMortality ratePatients